Ein Paarvergleich findet Originalpassagen, die den anderen Wirkstoff wörtlich nennen. Aussagen gelten für das jeweilige Präparat und seine Formulierung. Klassenbegriffe und abweichende Synonyme können fehlen. Kein Treffer bedeutet nicht, dass keine Wechselwirkung besteht.
RxNorm 05-Oct-2026 · geprüft 2026-10-25 · 1009 Präparate · 54812 Quellenpassagen · 148 strukturierte Aussagen. Automatisch aktualisiert, ohne menschliche Freigabe.
Wechselwirkungen · Combivir
Combivir 150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 7
HOS-088512 · Präparat HOS-083663
Drugs by Therapeutic Area
Interaction Recommendation
Geometric mean change (%) concerning co-
(Possible mechanism) administration
ANTIRETROVIRAL MEDICINAL PRODUCTS
Didanosine/Lamivudine Interaction not studied. No dosage adjustment
necessary.
Didanosine /Zidovudine Interaction not studied.
Stavudine/Lamivudine Interaction not studied. Combination not
Stavudine/Zidovudine In vitro antagonism of anti-HIV recommended.
activity between stavudine and
zidovudine could result in
decreased efficacy of both
drugs.
ANTI-INFECTIVE PRODUCTS
Atovaquone/Lamivudine Interaction not studied. As only limited data available
Atovaquone/Zidovudine Zidovudine AUC 33% the clinical significance is
(750 mg twice daily with Atovaquone AUC unknown.
food/200 mg thrice daily)
Clarithromycin/Lamivudine Interaction not studied. Separate administration of
Clarithromycin/Zidovudine Zidovudine AUC 12% Combivir and clarithromycin
(500 mg twice daily/100 mg by at least 2 hours
every 4 hours)
Trimethoprim/sulfamethoxazole Lamivudine: AUC 40% No Combivir dosage
(Co-trimoxazole)/Lamivudine adjustment necessary, unless
(160 mg/800 mg once daily for Trimethoprim: AUC patient has renal impairment
5 days/300 mg single dose) Sulfamethoxazole: AUC (See Section 4.2).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) atovaquone (HOS-086266) trimethoprim (HOS-085184) stavudine (HOS-088080) clarithromycin (HOS-084517) didanosine (HOS-085836)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2022-08-29T01:24:00Z · SHA-256 4660d55c0813c2571a95614bba44492fff03e6854bbe956eb43509fe476e679d · Passage ef0dd78ec8fb1f808137e8f5128b1cd7fa4540efa9cc39a15103836ffbdd97d9 · Zeichen 1146–3116 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 8
HOS-090592 · Präparat HOS-084095
Sirolimus is extensively metabolised by the CYP3A4 isozyme in the intestinal wall and liver.
Sirolimus is also a substrate for the multidrug efflux pump, P-glycoprotein (P-gp) located in the small
intestine. Therefore, absorption and the subsequent elimination of sirolimus may be influenced by
substances that affect these proteins. Inhibitors of CYP3A4 (such as ketoconazole, voriconazole,
itraconazole, telithromycin, or clarithromycin) decrease the metabolism of sirolimus and increase
sirolimus levels. Inducers of CYP3A4 (such as rifampin or rifabutin) increase the metabolism of
sirolimus and decrease sirolimus levels. Co-administration of sirolimus with strong inhibitors of
CYP3A4 or inducers of CYP3A4 is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifampin (HOS-088791) ketoconazole (HOS-084513) rifabutin (HOS-086262) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 159852d4b6d56d956ff9fb4bd74e5bc0c13922c9c8af0ccc6125f8aa005e10e7 · Zeichen 0–750 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 1 mg/mL oral solution · Abschnitt 4.5 · PDF-Seite 10
HOS-090616 · Präparat HOS-084095
Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole),
certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g.
ritonavir, indinavir, boceprevir, telaprevir), nicardipine, bromocriptine, cimetidine, danazol and
letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) letermovir (HOS-090621) nicardipine (HOS-090619) protease (HOS-085623) cimetidine (HOS-085835) clotrimazole (HOS-090574) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) fluconazole (HOS-087945) boceprevir (HOS-090617) clarithromycin (HOS-084517) troleandomycin (HOS-090575) bromocriptine (HOS-090620) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 5e78d73fd3b12aea3ede2eeac1a14a3dfb8e863d7c5ea6929177114d000b7a9c · Zeichen 5491–5914 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 29
HOS-090664 · Präparat HOS-084095
Sirolimus is extensively metabolised by the CYP3A4 isozyme in the intestinal wall and liver.
Sirolimus is also a substrate for the multidrug efflux pump, P-glycoprotein (P-gp) located in the small
intestine. Therefore, absorption and the subsequent elimination of sirolimus may be influenced by
substances that affect these proteins. Inhibitors of CYP3A4 (such as ketoconazole, voriconazole,
itraconazole, telithromycin, or clarithromycin) decrease the metabolism of sirolimus and increase
sirolimus levels. Inducers of CYP3A4 (such as rifampin or rifabutin) increase the metabolism of
sirolimus and decrease sirolimus levels. Co-administration of sirolimus with strong inhibitors of
CYP3A4 or inducers of CYP3A4 is not recommended (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): rifampin (HOS-088791) ketoconazole (HOS-084513) rifabutin (HOS-086262) voriconazole (HOS-084524) telithromycin (HOS-084523) itraconazole (HOS-084516) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 159852d4b6d56d956ff9fb4bd74e5bc0c13922c9c8af0ccc6125f8aa005e10e7 · Zeichen 0–750 im Abschnitt
Wechselwirkungen · Rapamune
Rapamune 0.5 mg coated tablets Rapamune 1 mg coated tablets Rapamune 2 mg coated tablets · Abschnitt 4.5 · PDF-Seite 30
HOS-090685 · Präparat HOS-084095
Inhibitors of CYP3A4 may decrease the metabolism of sirolimus and increase sirolimus blood levels.
Such inhibitors include certain antifungals (e.g. clotrimazole, fluconazole, itraconazole, voriconazole),
certain antibiotics (e.g. troleandomycin, telithromycin, clarithromycin), certain protease inhibitors (e.g.
ritonavir, indinavir, boceprevir, and telaprevir), nicardipine, bromocriptine, cimetidine, danazol and
letermovir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) letermovir (HOS-090621) nicardipine (HOS-090619) protease (HOS-085623) cimetidine (HOS-085835) clotrimazole (HOS-090574) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) danazol (HOS-085473) fluconazole (HOS-087945) boceprevir (HOS-090617) clarithromycin (HOS-084517) troleandomycin (HOS-090575) bromocriptine (HOS-090620) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-04T09:34:00Z · SHA-256 822914cb553b9bcf81064d714c9274d63e73d083445521dca5c314d6106f24d7 · Passage 238f7546225e192c0d4817ab6a1671062b9e93e1fd99e257fa0ce448f21b38a0 · Zeichen 5433–5860 im Abschnitt
Wechselwirkungen · Targretin
Targretin 75 mg soft capsules · Abschnitt 4.5 · PDF-Seite 5
HOS-091526 · Präparat HOS-084349
Effects of other substances on bexarotene
No formal studies to evaluate interactions with bexarotene have been conducted. On the basis of the
oxidative metabolism of bexarotene by cytochrome P450 3A4 (CYP3A4), coadministration with other
CYP3A4 substrates such as ketoconazole, itraconazole, protease inhibitors, clarithromycin and
erythromycin may theoretically lead to an increase in plasma bexarotene concentrations. Furthermore,
co-administration with CYP3A4 inducers such as rifampicin, phenytoin, dexamethasone or
phenobarbital may theoretically cause a reduction in plasma bexarotene concentrations.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) phenobarbital (HOS-085617) ketoconazole (HOS-084513) dexamethasone (HOS-084535) lead (HOS-085592) itraconazole (HOS-084516) clarithromycin (HOS-084517) erythromycin (HOS-084514) phenytoin (HOS-084531)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-12T12:14:00Z · SHA-256 3bf4d2f2fd7cbd6812f185953fbdb6223f58862715009080d9c1b2058c9f08b5 · Passage be5f9d9ff4d76d4b8473caec9b0e2e223aad8970f837bc7e78b263d876520dda · Zeichen 0–606 im Abschnitt
Wechselwirkungen · Trizivir
TRIZIVIR 300 mg/150 mg/300 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 8–9
HOS-108561 · Präparat HOS-093047
8
Stavudine/Zidovudine In vitro antagonism of anti-HIV
activity between stavudine and
zidovudine could result in
decreased efficacy of both
drugs.
ANTI-INFECTIVE PRODUCTS
Atovaquone/Abacavir Interaction not studied. As only limited data available
Atovaquone/Lamivudine Interaction not studied. the clinical significance is
Atovaquone/Zidovudine Zidovudine AUC 33% unknown.
(750 mg twice daily with Atovaquone AUC
food/200 mg thrice daily)
Clarithromycin/Abacavir Interaction not studied. Separate administration of
Clarithromycin/Lamivudine Interaction not studied. Trizivir and clarithromycin by
Clarithromycin/Zidovudine Zidovudine AUC 12% at least 2 hours
(500 mg twice daily/100 mg
every 4 hours)
Trimethoprim/sulfamethoxazole Interaction not studied. No Trizivir dosage adjustment
(Co-trimoxazole)/Abacavir necessary, unless patient has
Trimethoprim/sulfamethoxazole Lamivudine: AUC 40% renal impairment (See Section
(Co-trimoxazole)/Lamivudine 4.2).
(160mg/800mg once daily for 5 Trimethoprim: AUC
days/300mg single dose) Sulfamethoxazole: AUC When concomitant
administration with co-
(organic cation transporter trimoxazole is warranted,
inhibition) patients should be monitored
Trimethoprim/sulfamethoxazole Interaction not studied. clinically. High doses of
(Co-trimoxazole)/Zidovudine trimethoprim/
sulfamethoxazole for the
treatment of Pneumocystis
jirovecii pneumonia (PCP) and
toxoplasmosis have not been
studied and should be avoided.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): sulfamethoxazole (HOS-084533) atovaquone (HOS-086266) trimethoprim (HOS-085184) stavudine (HOS-088080) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-19T14:10:00Z · SHA-256 0fa44d429f9cace08dce2fd9d8c4f2ed838fc8cb0ed1b7cfc79bd6b9caa26349 · Passage 71bfdfc92b9301a18965d48965dbae21382ab47ace7b98ce7ba0a04318a98c78 · Zeichen 2506–4852 im Abschnitt
Wechselwirkungen · Prandin
Prandin 0.5 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-108637 · Präparat HOS-093055
The following substances may enhance and/or prolong the hypoglycaemic effect of repaglinide:
Gemfibrozil, clarithromycin, itraconazole, ketokonazole, trimethoprim, ciclosporin, deferasirox,
clopidogrel, other antidiabetic substances, monoamine oxidase inhibitors (MAOI), non selective beta
blocking substances, angiotensin converting enzyme (ACE)-inhibitors, salicylates, NSAIDs,
octreotide, alcohol, and anabolic steroids.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) deferasirox (HOS-088409) octreotide (HOS-085481) gemfibrozil (HOS-088403) itraconazole (HOS-084516) clopidogrel (HOS-087927) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage 30e88e7089f9852628a532c33d69941afc06407fddd7567690084ca1e89404a7 · Zeichen 1135–1558 im Abschnitt
Wechselwirkungen · Prandin
Prandin 0.5 mg tablets · Abschnitt 4.5 · PDF-Seite 5
HOS-108642 · Präparat HOS-093055
The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the
pharmacokinetics of repaglinide has been studied in healthy subjects. Co-administration of 200 mg
ketoconazole increased the repaglinide (AUC and Cmax) by 1.2-fold with profiles of blood glucose
concentrations altered by less than 8% when administered concomitantly (a single dose of 4 mg
repaglinide). Co-administration of 100 mg itraconazole, an inhibitor of CYP3A4, has also been
studied in healthy volunteers, and increased the AUC by 1.4-fold. No significant effect on the glucose
level in healthy volunteers was observed. In an interaction study in healthy volunteers, co-
administration of 250 mg clarithromycin, a potent mechanism-based inhibitor of CYP3A4, slightly
increased the repaglinide (AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental
AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold. The exact mechanism
of this interaction is not clear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) glucose (HOS-088412) itraconazole (HOS-084516) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage 87f43c80efc4087eb3a239c087cbe51c7443c8eec3071c799c234a855ad41389 · Zeichen 3892–4891 im Abschnitt
Wechselwirkungen · Prandin
Prandin 1 mg tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-108672 · Präparat HOS-093055
The following substances may enhance and/or prolong the hypoglycaemic effect of repaglinide:
Gemfibrozil, clarithromycin, itraconazole, ketokonazole, trimethoprim, ciclosporin, deferasirox,
clopidogrel, other antidiabetic substances, monoamine oxidase inhibitors (MAOI), non selective beta
blocking substances, angiotensin converting enzyme (ACE)-inhibitors, salicylates, NSAIDs,
octreotide, alcohol, and anabolic steroids.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) deferasirox (HOS-088409) octreotide (HOS-085481) gemfibrozil (HOS-088403) itraconazole (HOS-084516) clopidogrel (HOS-087927) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage 30e88e7089f9852628a532c33d69941afc06407fddd7567690084ca1e89404a7 · Zeichen 1136–1559 im Abschnitt
Wechselwirkungen · Prandin
Prandin 1 mg tablets · Abschnitt 4.5 · PDF-Seite 15
HOS-108677 · Präparat HOS-093055
The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the
pharmacokinetics of repaglinide has been studied in healthy subjects. Co-administration of 200 mg
ketoconazole increased the repaglinide (AUC and Cmax) by 1.2-fold with profiles of blood glucose
concentrations altered by less than 8% when administered concomitantly (a single dose of 4 mg
repaglinide). Co-administration of 100 mg itraconazole, an inhibitor of CYP3A4, has also been
studied in healthy volunteers, and increased the AUC by 1.4-fold. No significant effect on the glucose
level in healthy volunteers was observed. In an interaction study in healthy volunteers, co-
administration of 250 mg clarithromycin, a potent mechanism-based inhibitor of CYP3A4, slightly
increased the repaglinide (AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental
AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold. The exact mechanism
of this interaction is not clear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) glucose (HOS-088412) itraconazole (HOS-084516) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage 87f43c80efc4087eb3a239c087cbe51c7443c8eec3071c799c234a855ad41389 · Zeichen 3893–4892 im Abschnitt
Wechselwirkungen · Prandin
Prandin 2 mg tablets · Abschnitt 4.5 · PDF-Seite 25
HOS-108707 · Präparat HOS-093055
The following substances may enhance and/or prolong the hypoglycaemic effect of repaglinide:
Gemfibrozil, clarithromycin, itraconazole, ketokonazole, trimethoprim, ciclosporin, deferasirox,
clopidogrel, other antidiabetic substances, monoamine oxidase inhibitors (MAOI), non selective beta
blocking substances, angiotensin converting enzyme (ACE)-inhibitors, salicylates, NSAIDs,
octreotide, alcohol, and anabolic steroids.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): trimethoprim (HOS-085184) deferasirox (HOS-088409) octreotide (HOS-085481) gemfibrozil (HOS-088403) itraconazole (HOS-084516) clopidogrel (HOS-087927) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage 30e88e7089f9852628a532c33d69941afc06407fddd7567690084ca1e89404a7 · Zeichen 1136–1559 im Abschnitt
Wechselwirkungen · Prandin
Prandin 2 mg tablets · Abschnitt 4.5 · PDF-Seite 25
HOS-108712 · Präparat HOS-093055
The effect of ketoconazole, a prototype of potent and competitive inhibitors of CYP3A4, on the
pharmacokinetics of repaglinide has been studied in healthy subjects. Co-administration of 200 mg
ketoconazole increased the repaglinide (AUC and Cmax) by 1.2-fold with profiles of blood glucose
concentrations altered by less than 8% when administered concomitantly (a single dose of 4 mg
repaglinide). Co-administration of 100 mg itraconazole, an inhibitor of CYP3A4, has also been
studied in healthy volunteers, and increased the AUC by 1.4-fold. No significant effect on the glucose
level in healthy volunteers was observed. In an interaction study in healthy volunteers, co-
administration of 250 mg clarithromycin, a potent mechanism-based inhibitor of CYP3A4, slightly
increased the repaglinide (AUC) by 1.4-fold and Cmax by 1.7-fold and increased the mean incremental
AUC of serum insulin by 1.5-fold and the maximum concentration by 1.6-fold. The exact mechanism
of this interaction is not clear.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): ketoconazole (HOS-084513) glucose (HOS-088412) itraconazole (HOS-084516) clarithromycin (HOS-084517)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2018-05-14T02:00:00Z · SHA-256 4c973e31eb747a16f464340bcfe327b4eb470ef0597a3a9d0a9fc8e0d35f01d0 · Passage 87f43c80efc4087eb3a239c087cbe51c7443c8eec3071c799c234a855ad41389 · Zeichen 3893–4892 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra (80 mg + 20 mg) / ml oral solution · Abschnitt 4.5 · PDF-Seite 12–13
HOS-108863 · Präparat HOS-093083
12
CYP3A4 inhibition by concomitantly administered with
lopinavir/ritonavir. Kaletra.
Antianginal
Ranolazine Due to CYP3A inhibition by The concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and ranolazine is
of ranolazine are expected to contraindicated (see section 4.3).
increase.
Antiarrhythmics
Amiodarone, Dronedarone Amiodarone, Dronedarone: Concomitant administration of
Concentrations may be increased Kaletra and amiodarone or
due to CYP3A4 inhibition by dronedarone is contraindicated (see
lopinavir/ritonavir. section 4.3) as the risk of
arrhythmias or other serious
adverse reactions may be
increased.
Digoxin Digoxin: Caution is warranted and
Plasma concentrations may be therapeutic drug monitoring of
increased due to P-glycoprotein digoxin concentrations, if
inhibition by lopinavir/ritonavir. available, is recommended in case
The increased digoxin level may of co-administration of Kaletra and
lessen over time as P-gp digoxin. Particular caution should
induction develops. be used when prescribing Kaletra
in patients taking digoxin as the
acute inhibitory effect of ritonavir
on P-gp is expected to significantly
increase digoxin levels. Initiation
of digoxin in patients already
taking Kaletra is likely to result in
lower than expected increases of
digoxin concentrations.
Bepridil, Systemic Bepridil, Systemic Lidocaine, Caution is warranted and
Lidocaine, and Quinidine Quinidine: therapeutic drug concentration
Concentrations may be increased monitoring is recommended when
when co-administered with available.
lopinavir/ritonavir.
Antibiotics
Clarithromycin Clarithromycin: For patients with renal impairment
Moderate increases in (CrCL < 30 ml/min) dose reduction
clarithromycin AUC are expected of clarithromycin should be
due to CYP3A inhibition by considered (see section 4.4).
lopinavir/ritonavir. Caution should be exercised in
administering clarithromycin with
Kaletra to patients with impaired
hepatic or renal function.
Anticancer agents and kinase inhibitors
Abemaciclib Serum concentrations may be Co-administration of abemaciclib
increased due to CYP3A and Kaletra should be avoided. If
inhibition by ritonavir. this co-administration is judged
unavoidable, refer to the
abemaciclib SmPC for dosage
adjustment recommendations.
Monitor for ADRs related to
abemaciclib.
Apalutamide Apalutamide is a moderate to Decreased exposure of Kaletra may
strong CYP3A4 inducer and this result in potential loss of
may lead to a decreased exposure virological response.
of lopinavir/ritonavir.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) abemaciclib (HOS-086209) lidocaine (HOS-108866) apalutamide (HOS-086212) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592) clarithromycin (HOS-084517) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 2a6dc58dcb1aed961671098b7774afc6ab5284838d7c3becb73533d81f884e22 · Zeichen 9077–14069 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 200 mg/50 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 49–50
HOS-109006 · Präparat HOS-093083
49
Antiarrhythmics
Amiodarone, Amiodarone, Dronedarone: Concomitant administration of
Dronedarone Concentrations may be increased Kaletra and amiodarone or
due to CYP3A4 inhibition by dronedarone is contraindicated (see
lopinavir/ritonavir. section 4.3) as the risk of arrhythmias
or other serious adverse reactions
may be increased.
Digoxin Digoxin: Caution is warranted and therapeutic
Plasma concentrations may be drug monitoring of digoxin
increased due to P-glycoprotein concentrations, if available, is
inhibition by lopinavir/ritonavir. recommended in case of
The increased digoxin level may co-administration of Kaletra and
lessen over time as P-gp digoxin. Particular caution should be
induction develops. used when prescribing Kaletra in
patients taking digoxin as the acute
inhibitory effect of ritonavir on P-gp
is expected to significantly increase
digoxin levels. Initiation of digoxin
in patients already taking Kaletra is
likely to result in lower than expected
increases of digoxin concentrations.
Bepridil, Systemic Bepridil, Systemic Lidocaine, Caution is warranted and therapeutic
Lidocaine, and Quinidine: drug concentration monitoring is
Quinidine Concentrations may be increased recommended when available.
when co-administered with
lopinavir/ritonavir.
Antibiotics
Clarithromycin Clarithromycin: For patients with renal impairment
Moderate increases in (CrCL < 30 ml/min) dose reduction
clarithromycin AUC are expected of clarithromycin should be
due to CYP3A inhibition by considered (see section 4.4). Caution
lopinavir/ritonavir. should be exercised in administering
clarithromycin with Kaletra to
patients with impaired hepatic or
renal function.
Anticancer agents and kinase inhibitors
Abemaciclib Serum concentrations may be Co-administration of abemaciclib
increased due to CYP3A and Kaletra should be avoided. If
inhibition by ritonavir. this co-administration is judged
unavoidable, refer to the abemaciclib
SmPC for dosage adjustment
recommendations. Monitor for
ADRs related to abemaciclib.
Apalutamide Apalutamide is a moderate to Decreased exposure of Kaletra may
strong CYP3A4 inducer and this result in potential loss of virological
may lead to a decreased exposure response.
of lopinavir/ritonavir. In addition, co-administration of
apalutamide and Kaletra may lead to
Serum concentrations of serious adverse events including
apalutamide may be increased due seizure due to higher apalutamide
to CYP3A inhibition by levels. Concomitant use of Kaletra
lopinavir/ritonavir. with apalutamide is not
recommended.
Afatinib Afatinib: Caution should be exercised in
AUC: ↑ administering afatinib with Kaletra.
(Ritonavir 200 mg twice Cmax: ↑ Refer to the afatinib SmPC for
daily)
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) abemaciclib (HOS-086209) lidocaine (HOS-108866) apalutamide (HOS-086212) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) lead (HOS-085592) afatinib (HOS-086207) clarithromycin (HOS-084517) amiodarone (HOS-085596)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage e2bfc1f119ab72d4142e3587fc0d81da448b5ce69a5003d6154afba7723f33c1 · Zeichen 9850–14882 im Abschnitt
Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 84–85
HOS-109080 · Präparat HOS-093083
84
Fentanyl Fentanyl: Careful monitoring of adverse
Increased risk of side-effects effects (notably respiratory
(respiratory depression, sedation) depression but also sedation) is
due to higher plasma recommended when fentanyl is
concentrations because of concomitantly administered with
CYP3A4 inhibition by Kaletra.
lopinavir/ritonavir.
Antianginal
Ranolazine Due to CYP3A inhibition by The concomitant administration of
lopinavir/ritonavir, concentrations Kaletra and ranolazine is
of ranolazine are expected to contraindicated (see section 4.3).
increase.
Antiarrhythmics
Amiodarone, Amiodarone, Dronedarone: Concomitant administration of
Dronedarone Concentrations may be increased Kaletra and amiodarone or
due to CYP3A4 inhibition by dronedarone is contraindicated (see
lopinavir/ritonavir. section 4.3) as the risk of
arrhythmias or other serious adverse
reactions may be increased.
Digoxin Digoxin: Caution is warranted and
Plasma concentrations may be therapeutic drug monitoring of
increased due to P-glycoprotein digoxin concentrations, if available,
inhibition by lopinavir/ritonavir. is recommended in case of
The increased digoxin level may co-administration of Kaletra and
lessen over time as P-gp digoxin. Particular caution should
induction develops. be used when prescribing Kaletra in
patients taking digoxin as the acute
inhibitory effect of ritonavir on
P-gp is expected to significantly
increase digoxin levels. Initiation
of digoxin in patients already taking
Kaletra is likely to result in lower
than expected increases of digoxin
concentrations.
Bepridil, Systemic Bepridil, Systemic Lidocaine, Caution is warranted and
Lidocaine, and Quinidine: therapeutic drug concentration
Quinidine Concentrations may be increased monitoring is recommended when
when co-administered with available.
lopinavir/ritonavir.
Antibiotics
Clarithromycin Clarithromycin: For patients with renal impairment
Moderate increases in (CrCL < 30 ml/min) dose reduction
clarithromycin AUC are expected of clarithromycin should be
due to CYP3A inhibition by considered (see section 4.4).
lopinavir/ritonavir. Caution should be exercised in
administering clarithromycin with
Kaletra to patients with impaired
hepatic or renal function.
Anticancer agents and kinase inhibitors
Abemaciclib Serum concentrations may be Co-administration of abemaciclib
increased due to CYP3A and Kaletra should be avoided. If
inhibition by ritonavir. this co-administration is judged
unavoidable, refer to the
abemaciclib SmPC for dosage
adjustment recommendations.
Monitor for ADRs related to
abemaciclib.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): dronedarone (HOS-086144) abemaciclib (HOS-086209) lidocaine (HOS-108866) bepridil (HOS-085612) quinidine (HOS-085593) digoxin (HOS-086172) clarithromycin (HOS-084517) fentanyl (HOS-086196) amiodarone (HOS-085596) ranolazine (HOS-086141)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 441e910c1e6908f1a8725254649dcb0f97fdc57cf122c18523aa47225be733b2 · Zeichen 9035–13902 im Abschnitt
Wechselwirkungen · Glivec
Glivec 100 mg film-coated tablets Glivec 400 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-110215 · Präparat HOS-093339
Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. protease inhibitors
such as indinavir, lopinavir/ritonavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole
antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides such
as erythromycin, clarithromycin and telithromycin) could decrease metabolism and increase imatinib
concentrations. There was a significant increase in exposure to imatinib (the mean Cmax and AUC of
imatinib rose by 26% and 40%, respectively) in healthy subjects when it was co-administered with a
single dose of ketoconazole (a CYP3A4 inhibitor). Caution should be taken when administering
Glivec with inhibitors of the CYP3A4 family.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): indinavir (HOS-084518) lopinavir (HOS-086269) nelfinavir (HOS-084520) protease (HOS-085623) ketoconazole (HOS-084513) voriconazole (HOS-084524) telaprevir (HOS-090618) telithromycin (HOS-084523) itraconazole (HOS-084516) saquinavir (HOS-084522) boceprevir (HOS-090617) clarithromycin (HOS-084517) erythromycin (HOS-084514) ritonavir (HOS-084521) posaconazole (HOS-085622)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-12T09:28:00Z · SHA-256 838bc114dc50fcc5141e52ce7cbac64366b6fd4a03bb5a5e7a5ec09cf8be0b00 · Passage 8b33adeac7a33ce76a3ed583287cd02ab3b3048c12d43838a030dbd58a7f3ff4 · Zeichen 68–805 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 2.5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 5–6
HOS-111248 · Präparat HOS-093485
5
exposure (AUC) 2-fold with no change in Cmax. Although specific interactions have not been studied,
other protease inhibitors, such as saquinavir, and other CYP3A4 inhibitors, such as erythromycin,
clarithromycin, itraconazole and grapefruit juice should be co-administered with caution as they would
be expected to increase plasma concentrations of tadalafil (see section 4.4).
Consequently the incidence of the adverse reactions listed in section 4.8 might be increased.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) grapefruit juice (HOS-088787) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) erythromycin (HOS-084514)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 160fa6b7e0aa57843c8e4615e63d7e30c6731606141a97e7b1759e056bd24312 · Zeichen 855–1330 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 5 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 20
HOS-111297 · Präparat HOS-093485
Cytochrome P450 inhibitors
Tadalafil is principally metabolised by CYP3A4. A selective inhibitor of CYP3A4, ketoconazole
(200 mg daily), increased tadalafil (10 mg) exposure (AUC) 2-fold and Cmax by 15 %, relative to the
AUC and Cmax values for tadalafil alone. Ketoconazole (400 mg daily) increased tadalafil (20 mg)
exposure (AUC) 4-fold and Cmax by 22 %. Ritonavir, a protease inhibitor (200 mg twice daily), which
is an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil (20 mg)
exposure (AUC) 2-fold with no change in Cmax. Although specific interactions have not been studied,
other protease inhibitors, such as saquinavir, and other CYP3A4 inhibitors, such as erythromycin,
clarithromycin, itraconazole and grapefruit juice should be co-administered with caution as they would
be expected to increase plasma concentrations of tadalafil (see section 4.4).
Consequently the incidence of the adverse reactions listed in section 4.8 might be increased.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) erythromycin (HOS-084514) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 53b9e2340a89f1d59a03722250f75b8d0dc595f65a1a185a08867e88b06cfda4 · Zeichen 301–1275 im Abschnitt
Wechselwirkungen · Cialis
CIALIS 10 mg film-coated tablets CIALIS 20 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 34–35
HOS-111336 · Präparat HOS-093485
34
AUC and Cmax values for tadalafil alone. Ketoconazole (400 mg daily) increased tadalafil (20 mg)
exposure (AUC) 4-fold and Cmax by 22 %. Ritonavir, a protease inhibitor (200 mg twice daily), which
is an inhibitor of CYP3A4, CYP2C9, CYP2C19, and CYP2D6, increased tadalafil (20 mg)
exposure (AUC) 2-fold with no change in Cmax. Although specific interactions have not been studied,
other protease inhibitors, such as saquinavir, and other CYP3A4 inhibitors, such as erythromycin,
clarithromycin, itraconazole and grapefruit juice should be co-administered with caution as they would
be expected to increase plasma concentrations of tadalafil (see section 4.4).
Consequently the incidence of the adverse reactions listed in section 4.8 might be increased.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): protease (HOS-085623) ketoconazole (HOS-084513) grapefruit juice (HOS-088787) itraconazole (HOS-084516) saquinavir (HOS-084522) clarithromycin (HOS-084517) erythromycin (HOS-084514) ritonavir (HOS-084521)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-28T14:23:00Z · SHA-256 545fdb0c46550348a52d431b0929b4f86d6314f2661c3c334d55f57753aad337 · Passage 496d2586435e56945a5b47b4ba3fc23de03c2fefcb3cca9a8cef5e16b90aa2c2 · Zeichen 574–1331 im Abschnitt
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.